Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF)

Walter J. McConathy, Sulabha Paranjape, Linda Mooberry, Sabitha Buttreddy, Maya P. Nair, Andras G. Lacko

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Dilauryl fluorescein (DLF) is a lipid soluble molecule that becomes fluorescent when lauric acid is removed by hydrolysis The purpose of these studies was to evaluate DLF as a potential probe for the function of reconstituted high-density lipoproteins (rHDL) as hydrophobic drug transport vehicles. The DLF containing rHDL nanoparticles were characterized regarding their physical/chemical properties, including molecular diameter, molecular weight, chemical composition, and buoyant density. We investigated the uptake of DLF from rHDL in cells that overexpress the scavenger receptor (SR-B1), known to facilitate the selective cellular uptake of cholesteryl esters from HDL. These studies show that DLF can be incorporated into rHDL and redistributed in the plasma compartment. In addition, these studies demonstrated an enhanced uptake and hydrolysis of DLF from rHDL by cells that overexpress the SR-B1 receptor, suggesting the involvement of a receptor mediated mechanism. The incorporation of DLF into the rHDL nanoparticles appear to protect against hydrolysis in the systemic circulation based on the lower rate of rHDL/DLF hydrolysis compared with the free DLF during incubation with human plasma. DLF may thus be used as a probe to track the movement and metabolism of HDL core constituents, including cancer chemotherapeutic agents.

Original languageEnglish
Pages (from-to)113-120
Number of pages8
JournalDrug Delivery and Translational Research
Volume1
Issue number2
DOIs
StatePublished - 1 Apr 2011

Fingerprint

HDL Lipoproteins
Fluorescein
Pharmaceutical Preparations
Hydrolysis
lauric acid
Nanoparticles
Scavenger Receptors
Molecular Weight
Lipids

Keywords

  • Chemotherapy
  • Controlled release
  • Drug delivery
  • Protective transport
  • Receptor mediated uptake
  • Reconstituted HDL

Cite this

@article{f9ccc0d9107a4a1ab2f6109802afc7ab,
title = "Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF)",
abstract = "Dilauryl fluorescein (DLF) is a lipid soluble molecule that becomes fluorescent when lauric acid is removed by hydrolysis The purpose of these studies was to evaluate DLF as a potential probe for the function of reconstituted high-density lipoproteins (rHDL) as hydrophobic drug transport vehicles. The DLF containing rHDL nanoparticles were characterized regarding their physical/chemical properties, including molecular diameter, molecular weight, chemical composition, and buoyant density. We investigated the uptake of DLF from rHDL in cells that overexpress the scavenger receptor (SR-B1), known to facilitate the selective cellular uptake of cholesteryl esters from HDL. These studies show that DLF can be incorporated into rHDL and redistributed in the plasma compartment. In addition, these studies demonstrated an enhanced uptake and hydrolysis of DLF from rHDL by cells that overexpress the SR-B1 receptor, suggesting the involvement of a receptor mediated mechanism. The incorporation of DLF into the rHDL nanoparticles appear to protect against hydrolysis in the systemic circulation based on the lower rate of rHDL/DLF hydrolysis compared with the free DLF during incubation with human plasma. DLF may thus be used as a probe to track the movement and metabolism of HDL core constituents, including cancer chemotherapeutic agents.",
keywords = "Chemotherapy, Controlled release, Drug delivery, Protective transport, Receptor mediated uptake, Reconstituted HDL",
author = "McConathy, {Walter J.} and Sulabha Paranjape and Linda Mooberry and Sabitha Buttreddy and Nair, {Maya P.} and Lacko, {Andras G.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s13346-010-0012-0",
language = "English",
volume = "1",
pages = "113--120",
journal = "Drug Delivery and Translational Research",
issn = "2190-393X",
publisher = "Springer Publishing Company",
number = "2",

}

Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). / McConathy, Walter J.; Paranjape, Sulabha; Mooberry, Linda; Buttreddy, Sabitha; Nair, Maya P.; Lacko, Andras G.

In: Drug Delivery and Translational Research, Vol. 1, No. 2, 01.04.2011, p. 113-120.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF)

AU - McConathy, Walter J.

AU - Paranjape, Sulabha

AU - Mooberry, Linda

AU - Buttreddy, Sabitha

AU - Nair, Maya P.

AU - Lacko, Andras G.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Dilauryl fluorescein (DLF) is a lipid soluble molecule that becomes fluorescent when lauric acid is removed by hydrolysis The purpose of these studies was to evaluate DLF as a potential probe for the function of reconstituted high-density lipoproteins (rHDL) as hydrophobic drug transport vehicles. The DLF containing rHDL nanoparticles were characterized regarding their physical/chemical properties, including molecular diameter, molecular weight, chemical composition, and buoyant density. We investigated the uptake of DLF from rHDL in cells that overexpress the scavenger receptor (SR-B1), known to facilitate the selective cellular uptake of cholesteryl esters from HDL. These studies show that DLF can be incorporated into rHDL and redistributed in the plasma compartment. In addition, these studies demonstrated an enhanced uptake and hydrolysis of DLF from rHDL by cells that overexpress the SR-B1 receptor, suggesting the involvement of a receptor mediated mechanism. The incorporation of DLF into the rHDL nanoparticles appear to protect against hydrolysis in the systemic circulation based on the lower rate of rHDL/DLF hydrolysis compared with the free DLF during incubation with human plasma. DLF may thus be used as a probe to track the movement and metabolism of HDL core constituents, including cancer chemotherapeutic agents.

AB - Dilauryl fluorescein (DLF) is a lipid soluble molecule that becomes fluorescent when lauric acid is removed by hydrolysis The purpose of these studies was to evaluate DLF as a potential probe for the function of reconstituted high-density lipoproteins (rHDL) as hydrophobic drug transport vehicles. The DLF containing rHDL nanoparticles were characterized regarding their physical/chemical properties, including molecular diameter, molecular weight, chemical composition, and buoyant density. We investigated the uptake of DLF from rHDL in cells that overexpress the scavenger receptor (SR-B1), known to facilitate the selective cellular uptake of cholesteryl esters from HDL. These studies show that DLF can be incorporated into rHDL and redistributed in the plasma compartment. In addition, these studies demonstrated an enhanced uptake and hydrolysis of DLF from rHDL by cells that overexpress the SR-B1 receptor, suggesting the involvement of a receptor mediated mechanism. The incorporation of DLF into the rHDL nanoparticles appear to protect against hydrolysis in the systemic circulation based on the lower rate of rHDL/DLF hydrolysis compared with the free DLF during incubation with human plasma. DLF may thus be used as a probe to track the movement and metabolism of HDL core constituents, including cancer chemotherapeutic agents.

KW - Chemotherapy

KW - Controlled release

KW - Drug delivery

KW - Protective transport

KW - Receptor mediated uptake

KW - Reconstituted HDL

UR - http://www.scopus.com/inward/record.url?scp=84861311694&partnerID=8YFLogxK

U2 - 10.1007/s13346-010-0012-0

DO - 10.1007/s13346-010-0012-0

M3 - Article

VL - 1

SP - 113

EP - 120

JO - Drug Delivery and Translational Research

JF - Drug Delivery and Translational Research

SN - 2190-393X

IS - 2

ER -